Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, randomized, comparative study of Zerit (d4T) [stavudine] + Videx (ddI) [didanosine] + Crixivan [indinavir] versus Retrovir (AZT) [zidovudine] + Epivir (3TC) [lamivudine] + Crixivan in HIV-infected, antiretroviral naive subjects with CD4 cell counts of 200 - 700/mm3 and HIV RNA baseline copy number of at least 10,000 copies/mL

Next Previous
X
Search
Trial Profile

An open label, randomized, comparative study of Zerit (d4T) [stavudine] + Videx (ddI) [didanosine] + Crixivan [indinavir] versus Retrovir (AZT) [zidovudine] + Epivir (3TC) [lamivudine] + Crixivan in HIV-infected, antiretroviral naive subjects with CD4 cell counts of 200 - 700/mm3 and HIV RNA baseline copy number of at least 10,000 copies/mL

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Didanosine (Primary) ; Indinavir (Primary) ; Lamivudine (Primary) ; Stavudine (Primary) ; Zidovudine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top